Welcome Patients & Caregivers

András’ story shows that in aggressive, fast-progressing cancers, time is not just a clinical variable, it is a human one. While the diagnosis itself may not change, the experience of reaching it can. ROSE cannot cure advanced disease, but it can reduce diagnostic delays and ease suffering by giving patients and families earlier clarity, support, and time to prepare.

In his Transylvanian town, András is not just a patient.

He is a father, a grandfather, an uncle, a neighbor , and a familiar and respected presence in the community. After a lifetime of work, András had just retired. He was finally ready to slow down, enjoy time with his family, and be more present for his grandchildren. He could live the ordinary days he had worked so hard to earn.

None of us imagined how quickly those plans would be interrupted.

At first, the signs were subtle. He was more tired than usual. Breathing became more difficult. His face began to swell. Like many men of his generation, András tried to push through it. He didn’t complain. He didn’t want to worry anyone.

When medical tests were finally done, life changed all at once. The scans revealed a large mass in his chest, pressing on a major blood vessel. There was a tumor in his lung, and the cancer had already metastasized to his liver. The disease was already advanced.

Doctors chose the fastest and safest way to get answers: a liver biopsy. The procedure itself went smoothly. But what followed was the hardest part: waiting. The first results raised concerning findings, but the amount of tissue obtained was limited. Because of this, additional immunohistochemical (IHC) testing was required, which extended the time needed to confirm the diagnosis.

During that time, András’ condition worsened in ways that were deeply exhausting. Night were the hardest, and he could no longer sleep. Breathing was uncomfortable, and the pressure in his chest made rest nearly impossible. For our family, time felt stretched and heavy, filled with questions and quiet fear.

Then, his doctors made a collective decision that most likely saved his life. They began treatment before his final results were available. Waiting any longer was simply no longer an option.

Sixteen days passed between the first imaging tests and the final confirmed diagnosis. Ten days later, after additional specialized testing, the diagnosis was confirmed as stage IV small-cell lung carcinoma – a fast-moving disease that leaves little time to react.

For our family, and for everyone who knew András, the shock was profound. A man who had just stepped into retirement, full intent on enjoying his remaining years with his children, grandchildren, nieces, and nephews, suddenly found himself navigating a reality none of us were prepared for.

This story is not about blame. We are deeply grateful for the doctors, nurses, and medical teams who acted quickly and decisively when András’s life was at risk.

In a situation like András’s, where the cancer was already advanced and moving fast, we understand that no system, no test, and no procedure could have changed the diagnosis itself. What can change, however, is the experience of reaching that diagnosis.

In advanced, fast-progressing cancers, reducing diagnostic delays has meaningful clinical and psychosocial impact.

With Rapid On-Site Evaluation (ROSE), biopsy samples are reviewed immediately during the procedure, on site or remotely, to confirm that diagnostically useful tissue has been collected. This real-time assessment allows adjustments to sampling as needed, reducing repeat biopsies and delays.

ROSE does not offer cures, but it reduces time spent waiting and wishing for an answer.

In aggressive, stage IV cancers, those days matter deeply. Less waiting can mean earlier clarity and earlier support, but also more time for families to come together. When answers arrive sooner, families can spend less time suspended in fear and more time focusing on comfort, connection, and what matters most.

We know that many hospitals do not have access to ROSE, not because of a lack of care or skill, but because of limited resources. Our hope is simply that, where possible, tools like ROSE might be considered, so that other families facing aggressive cancers can spend less time waiting and more time healing together.

András’s story is about presence, resilience, and the fragile space between diagnosis and understanding, a space where families hold on to each other and to the moments that still matter.

When cancer moves fast, compassion must move just as fast.

András’ story shows that in aggressive, fast-progressing cancers, time is not just a clinical variable, it is a human one. While the diagnosis itself may not change, the experience of reaching it can. ROSE cannot cure advanced disease, but it can reduce diagnostic delays and ease suffering by giving patients and families earlier clarity, support, and time to prepare.

In his Transylvanian town, András is not just a patient.

He is a father, a grandfather, an uncle, a neighbor , and a familiar and respected presence in the community. After a lifetime of work, András had just retired. He was finally ready to slow down, enjoy time with his family, and be more present for his grandchildren. He could live the ordinary days he had worked so hard to earn.

None of us imagined how quickly those plans would be interrupted.

At first, the signs were subtle. He was more tired than usual. Breathing became more difficult. His face began to swell. Like many men of his generation, András tried to push through it. He didn’t complain. He didn’t want to worry anyone.

When medical tests were finally done, life changed all at once. The scans revealed a large mass in his chest, pressing on a major blood vessel. There was a tumor in his lung, and the cancer had already metastasized to his liver. The disease was already advanced.

Doctors chose the fastest and safest way to get answers: a liver biopsy. The procedure itself went smoothly. But what followed was the hardest part: waiting. The first results raised concerning findings, but the amount of tissue obtained was limited. Because of this, additional immunohistochemical (IHC) testing was required, which extended the time needed to confirm the diagnosis.

During that time, András’ condition worsened in ways that were deeply exhausting. Night were the hardest, and he could no longer sleep. Breathing was uncomfortable, and the pressure in his chest made rest nearly impossible. For our family, time felt stretched and heavy, filled with questions and quiet fear.

Then, his doctors made a collective decision that most likely saved his life. They began treatment before his final results were available. Waiting any longer was simply no longer an option.

Sixteen days passed between the first imaging tests and the final confirmed diagnosis. Ten days later, after additional specialized testing, the diagnosis was confirmed as stage IV small-cell lung carcinoma – a fast-moving disease that leaves little time to react.

For our family, and for everyone who knew András, the shock was profound. A man who had just stepped into retirement, full intent on enjoying his remaining years with his children, grandchildren, nieces, and nephews, suddenly found himself navigating a reality none of us were prepared for.

This story is not about blame. We are deeply grateful for the doctors, nurses, and medical teams who acted quickly and decisively when András’s life was at risk.

In a situation like András’s, where the cancer was already advanced and moving fast, we understand that no system, no test, and no procedure could have changed the diagnosis itself. What can change, however, is the experience of reaching that diagnosis.

In advanced, fast-progressing cancers, reducing diagnostic delays has meaningful clinical and psychosocial impact.

With Rapid On-Site Evaluation (ROSE), biopsy samples are reviewed immediately during the procedure, on site or remotely, to confirm that diagnostically useful tissue has been collected. This real-time assessment allows adjustments to sampling as needed, reducing repeat biopsies and delays.

ROSE does not offer cures, but it reduces time spent waiting and wishing for an answer.

In aggressive, stage IV cancers, those days matter deeply. Less waiting can mean earlier clarity and earlier support, but also more time for families to come together. When answers arrive sooner, families can spend less time suspended in fear and more time focusing on comfort, connection, and what matters most.

We know that many hospitals do not have access to ROSE, not because of a lack of care or skill, but because of limited resources. Our hope is simply that, where possible, tools like ROSE might be considered, so that other families facing aggressive cancers can spend less time waiting and more time healing together.

András’s story is about presence, resilience, and the fragile space between diagnosis and understanding, a space where families hold on to each other and to the moments that still matter.

When cancer moves fast, compassion must move just as fast.